PPT-Raltegravir + Darunavir/r versus TDF-FTC + Darunavir/r RADAR Trial

RADAR Trial Raltegravir Darunavirr versus TDFFTC Darunavirr RADAR Study Design Source Bedimo RJ et al PLoS One 20149e106221 Darunavir QD Ritonavir QD Raltegravir BID . Fostemsavir. , . prodrug. of . temsavir. . (. attachment . inhibitor. ). AI438011 . Study. TAF (TFV . prodrug. ). Study . 292-0102. Study . 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). de . l’étude. Critère. principal . –. puissance . statistique. : pour 64 infections par le VIH-1, puissance de 80 % pour . détecter. . une. diminution relative de 50 % de . l’incidence. SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A4001078. VEMAN. . MODERN. A4001078 . Study. : ATV/r + MVC vs ATV/r + TDF/FTC . Design. ≥ 16 . years. HIV+. Antiretroviral. . naive. HIV-1 RNA ≥ 1 000 c/. STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. FLAMINGO. GS-236-0103. ACTG A5257. WAVES . ARIA . Squires K. Lancet HIV 2016; 3(9):e410-e420. Design. Objective. Non inferiority of EVG/C/FTC/TDF at W48: % HIV RNA < 50 c/. mL. by intention. to treat, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = -12%). Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. DUAL-GESIDA. Dual Maintenance ART with RTV-Boosted Darunavir + . Lamivudine. DUAL . GESIDA: . Study Design. Source: . Pulido. . F, . et al. . Clin Infect . Dis..  . 2017;65:2112-8.. DRV + RTV + 3TC. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. Study GS-366-1216. Switch from TDF to TAF, each with RPV and FTC. Study GS-366-1216: Design. Source: . Orkin. C et al. Lancet HIV. 2017;4:e195-e204.. *. NOTE. :. of 632 participants randomized, 2 were never treated (630 individuals treated). ROCKET II. Switching to TDF-FTC from ABC-3TC . for Hyperlipidemia . ROCKET II. : Study Design. Source: Behrens G, et al. . Antivir. . Ther. . . 2012;17:1011-20.. TDF-FTC + LPV-RTV. (. n = . 42). ABC-3TC + LPV-RTV. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. Andrew Hill, Francois Venter, Eric . Delaporte. , . Simiso. Sokhela, Charles . Kouanfack. , . Michelle Moorhouse. , Kaitlyn McCann, Bryony Simmons. , . Alexandra . Calmy. Disclosures. Speaker fees and honoraria from Gilead Sciences, AbbVie, Cipla, Johnson and Johnson, Sanofi, Pfizer, ViiV Healthcare, Mylan and Southern African HIV Clinicians Society. POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR . SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed .